Shopping Cart

Your shopping cart is currently empty

740 Y-P

Name: 740 Y-P
Brand: TargetMol
SKU: TQ0003
Price: 89 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. TQ0003Cas No. 1236188-16-1

Alias PDGFR 740Y-P, 740YPDGFR

740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85.

740 Y-P

😃Good

Purity: 99.87%

Catalog No. TQ0003Alias PDGFR 740Y-P, 740YPDGFRCas No. 1236188-16-1

740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$89	In Stock	In Stock
2 mg	$139	In Stock	In Stock
5 mg	$265	In Stock	In Stock
10 mg	$393	In Stock	-
25 mg	$658	7-10 days	7-10 days
50 mg	$937	7-10 days	7-10 days

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.87%

Resource Download

COA LCMS

Product Introduction

Bioactivity

Description	740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85.
Targets&IC50	NOZ cells:9.91 μM, SGC - 996 Cell:9.32 μM
In vitro	METHODS: C2 muscle cells were treated with 740 Y-P (50 μg/mL) for 48 hours, and the cell cycle was observed and analyzed using an ultraviolet fluorescence microscope. RESULTS: Mitosis in the 740 Y-P-specific stimulation medium was superior to EGF or FGF in stimulating the entry into the S phase. It showed that the percentage of S phase cells in C2 cells was 48.3%. [1] METHODS: PC12 cells were treated with 740 YP (30 μM) for 24 hours, and the LC3-II/LC3-I levels were detected by western blot. RESULTS: 740 YP significantly inhibited the LC3-II/LC3-I levels in PC12 cells induced by GO. [2]
In vivo	METHODS: To study the neuroprotective effect of 740 Y-P, 740 Y-P (10 mg/kg) was intraperitoneally injected into the rat model of Alzheimer's disease (AD) for 6 weeks. RESULTS: 740 Y-P can reduce the ROS (reactive oxygen species) level in hippocampal tissue after treatment with Aβ(25-32), and increase the phosphorylation degree of AKT and PI3K. This indicates that 740 Y-P has a certain neuroprotective effect in vivo, which may be achieved by activating the PI3K/Akt signaling pathway. [3] METHODS: To study the role of 740 Y-P in cardiac hypertrophy, 740 Y-P (10 mg/kg) was intraperitoneally injected into mice for 6 weeks. RESULTS: 740 Y-P can significantly increase the ratio of heart weight to body weight (HW/BW) and the ratio of heart weight to tibial length (HW/TL), and increase the cross-sectional area of cardiomyocytes. Furthermore, 740 Y-P can also increase the expression of hypertrophy related genes such as ANP, BNP and β-MHC in cardiomyocytes, indicating that it can promote cardiac hypertrophy in vivo. [4] METHODS: To study the analgesic effect of 740 Y-P, 740 Y-P (1, 5, 10, 20 µg/5 µL) was intrathecally injected into a mouse model of chronic constriction injury of the sciatic nerve (CCI). RESULTS: At doses of 10 and 20 µg/5 µL, 740 Y-P can significantly alleviate tactile and thermal hypersensitivity caused by CCI. 740 Y-P showed significant analgesic effects within 1.5, 3 and 5 hours after injection, but the effect was no longer significant after 24 hours. [5]
Synonyms	PDGFR 740Y-P, 740YPDGFR

Chemical Properties

Molecular Weight	3270.7
Formula	C₁₄₁H₂₂₂N₄₃O₃₉PS₃
Cas No.	1236188-16-1
Smiles	C([C@@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC=2C=3C(NC2)=CC=CC3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@@H](CC4=CC=C(OP(=O)(O)O)C=C4)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CO)=O)CCSC)=O)CC(O)=O)=O)CCSC)=O)=O)=O)=O)CC(O)=O)=O)CO)=O)CCCCN)=O)CCCCN)=O)=O)CCCCN)=O)CCSC)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CC(N)=O)=O)CCC(N)=O)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CCCCN)=O)[C@H](CC)C)=O)C=5C=6C(NC5)=CC=CC6
Relative Density.	1.51 g/cm3 (Predicted)
Color	White
Appearance	Solid
Sequence	Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Ser-Asp-Gly-Gly-{Tyr(PO2)}-Met-Asp-Met-Ser
Sequence Short	RQIKIWFQNRRMKWKKSDGG-{Tyr(PO2)}-MDMS

Storage & Solubility Information

Storage

store at low temperature,store under nitrogen,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (15.29 mM), Sonication is recommended.

H2O: 5.5 mg/mL (1.68 mM), when pH is adjusted with HCl. Sonication is recommmended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (0.61 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	0.3057 mL	1.5287 mL	3.0574 mL	15.2872 mL

DMSO

	1mg	5mg	10mg	50mg
5 mM	0.0611 mL	0.3057 mL	0.6115 mL	3.0574 mL
10 mM	0.0306 mL	0.1529 mL	0.3057 mL	1.5287 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH₂O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH₂O TargetMol | reagent

mix well and clarify

For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.

All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc